| Biological Sciences | Lifetime | 34 | US 20 | 99.99 |
| Medical and Health Sciences | Lifetime | 331 | US 185 | 99.99 |
| Oncology | Lifetime | 1 | US 1 | 100.00 |
| Immunology | Lifetime | 2 | US 1 | 100.00 |
| Genetics | Lifetime | 304 | US 168 | 99.32 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 401 | US 228 | 99.04 |
| Pulmonary and Respiratory Medicine | Lifetime | 600 | US 318 | 99.13 |
| Biotechnology | Lifetime | 118 | US 29 | 98.42 |
| Oncology | 2021-2025 | 235 | US 99 | 98.01 |
| Immunology | 2021-2025 | 290 | US 96 | 92.99 |
| Immunotherapy and Immune Responses | Lifetime | 1 | US 1 | 100.00 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 1 | US 1 | 99.99 |
| Virus-based gene therapy research | Lifetime | 1 | US 1 | 99.98 |
| Immune Cell Function and Interaction | Lifetime | 2 | US 2 | 99.99 |
| CAR-T cell therapy research | Lifetime | 1 | US 1 | 100.00 |
| vaccines and immunoinformatics approaches | Lifetime | 1 | US 1 | 99.98 |
| Cancer Research and Treatments | Lifetime | 4 | US 2 | 99.94 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 24 | US 18 | 99.92 |
| T-cell and B-cell Immunology | Lifetime | 33 | US 24 | 99.92 |
| RNA Interference and Gene Delivery | Lifetime | 70 | US 44 | 99.68 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 30 | US 17 | 99.38 |
| Sarcoma Diagnosis and Treatment | Lifetime | 152 | US 81 | 99.28 |
| Viral Infectious Diseases and Gene Expression in Insects | Lifetime | 205 | US 116 | 98.10 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 98 | US 55 | 97.25 |
| Glycosylation and Glycoproteins Research | Lifetime | 644 | US 290 | 98.09 |
| Cytomegalovirus and herpesvirus research | Lifetime | 570 | US 329 | 97.63 |
| Vascular Tumors and Angiosarcomas | Lifetime | 169 | US 85 | 97.60 |
| Renal cell carcinoma treatment | Lifetime | 670 | US 350 | 97.36 |
| Transgenic Plants and Applications | Lifetime | 295 | US 102 | 96.64 |
| Cancer Cells and Metastasis | Lifetime | 999 | US 430 | 96.31 |
| Cutaneous Melanoma Detection and Management | Lifetime | 498 | US 225 | 96.66 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 290 | US 149 | 94.43 |
| Hematological disorders and diagnostics | Lifetime | 550 | US 256 | 93.39 |
| Melanoma and MAPK Pathways | Lifetime | 824 | US 395 | 92.56 |
| Chemotherapy-related skin toxicity | Lifetime | 466 | US 225 | 87.68 |
| Macrophage Migration Inhibitory Factor | Lifetime | 568 | US 235 | 86.27 |
| Immunotherapy and Immune Responses | 2021-2025 | 144 | US 50 | 97.74 |
| CAR-T cell therapy research | 2021-2025 | 221 | US 123 | 98.44 |
| Immune Cell Function and Interaction | 2021-2025 | 410 | US 151 | 95.02 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 884 | US 325 | 96.56 |
